Genesis Energy LP (NYSE:GEL) reported disappointing earnings for the fourth quarter of 2024, missing analysts' expectations with an earnings per share (EPS) of -0.58 compared to the forecasted -0.26.

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

The Imperial Leather owner's shares jumped over 10 per cent to 87.8p in early trading, far ahead of investment trust PRS Reit ...

Here are the prospects to know before the offseason kicks into gear. Their names could rise up draft boards before you know ...